After announcing plans to go public in August, Gaithersburg biotech company GlycoMimetics mysteriously revealed in November that it would postpone its impending IPO. There wasn’t much sign of why the company decided to halt its plan, and there still really isn’t. However, the Washington Business Journal reported Friday that GlycoMimetics is back on track to go public sometime in the near future. Referencing the company’s amended SEC S-1 filing, though, the terms it had earlier set – between $14 and $16 for the four million shares – were no longer listed. At a midpoint share price, that would’ve raised about $60 million for the company specializing in treatments for sickle cell anemia and acute myeloid leukemia.
Help employers find you! Check out all the jobs and post your resume.
